| Ytd | -10.99% | |
| 1y | 54.69% |
| Open | 6.64 | Prev Close | 6.65 | Low | 6.64 | High | 7.17 | Mkt Cap | 381.76M |
| Vol | 88.36K | Avg Vol | 200.75K | EPS | -0.71 | P/E | -9.98 | Forward P/E | -7.26 |
| Beta | 1.01 | Short Ratio | 3.88 | Inst. Own | 31.61% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-06 | 50-d Avg | 6.58 | 200-d Avg | 7.19 | 1yr Est | 7.00 |
DMAC News
DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call Transcript
DiaMedica Therapeutics NASDAQ: DMAC said its second-quarter progress centered on advancing DM199 acr
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma
US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing no
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma
DiaMedica Therapeutics Inc. (DMAC) Q1 2026 Earnings Call Transcript
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma
DiaMedica Therapeutics (NASDAQ: DMAC) President and CEO Rick Pauls outlined the company's developmen
DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call Transcript
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) will release earnings for its fourth quarter after the cl
Shares of DiaMedica Therapeutics, Inc. (NASDAQ: DMAC - Get Free Report) have received a consensus ra
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharma
DiaMedica Therapeutics (NASDAQ: DMAC - Get Free Report) is expected to be releasing its Q4 2025 resu
DiaMedica Therapeutics, Inc. (NASDAQ: DMAC - Get Free Report) has earned a consensus rating of "Mode
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report q
Companies Reporting Before The Bell • Caledonia Mining (AMEX:CMCL) is expected to report earnings f
Companies Reporting Before The Bell • Wix.com (NASDAQ:WIX) is estimated to report earnings for i
Upgrades
Gainers USA Truck, Inc. (NASDAQ: USAK) shares climbed 112.6% to close at $31.00 on Friday. DB Sc
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report qu
During Wednesday's morning trading, 400 companies set new 52-week lows.
Gainers
Gainers Red Cat Holdings, Inc. (NASDAQ: RCAT) shares jumped 54.1% to $3.6998 after the company sa
Companies Reporting Before The Bell • Wireless Telecom Group (AMEX:WTT) is likely to report earn
Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnin
Gainers
Gainers
Gainers